Demographic, clinical, and laboratory characteristics in patients with positive ANCA (n = 129).
| Characteristics | PR3-ANCA, n = 81 | MPO-ANCA, n = 48 | p |
|---|---|---|---|
| Age at diagnosis, yrs, mean ± SD | 56.4 ± 15.8 | 65.9 ± 11.3 | < 0.001 |
| Female, n (%) | 41 (50.6) | 27 (56.3) | 0.5 |
| Creatinine at diagnosis, mg/dl, median (IQR) | 1.40 (1.01–3.37) | 3.16 (1.61–7.44) | 0.01 |
| CRP at diagnosis, mg/dl, median (IQR) | 9.5 (2.3–19.0) | 5.4 (1.3–12.9) | 0.4 |
| Creatinine last assessment*, mg/dl, median (IQR) | 1.17 (0.87–1.55) | 1.23 (0.94–2.06) | 0.7 |
| GFR < 50, n (%)* | 14/77 (18.2) | 13/34 (38.2) | 0.02 |
| DEI, mean ± SD | 6.7 ± 2.4 | 6.0 ± 2.9 | 0.1 |
| Death, n (%) | 10 (12.3) | 12 (25) | 0.06 |
| ESRD, n (%) | 2 (2.5) | 14 (29.2) | < 0.001 |
↵* Patients alive with native kidney function at last followup. ANCA: antineutrophil cytoplasmic antibodies; PR3: proteinase 3; MPO: myeloperoxidase; IQR: interquartile range; CRP: C-reactive protein; GFR: glomerular filtration rate; DEI: disease extent index; ESRD: endstage renal disease (defined as either commencement of chronic dialysis or renal transplantation at any time during the followup from diagnosis to June 2014).